The cystic fibrosis therapeutics market of North America is evaluated to grow at a high pace and record a CAGR of 10.07% over the forecast period of 2020-2028. One of the main factors propelling the demand in the market region is the continuous research and development of drugs and therapy for prevailing ailments of cystic fibrosis. In order to further study the North American market of cystic fibrosis therapeutics, the region is divided into the United States and Canada.

NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

North America Cystic Fibrosis Therapeutics Market by Route of Administration (Inhale, Oral) by Drug Class (CFTR Modulators, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplements) and by Geography.

Request free sample

Report Summary

In order to further study the North American market of cystic fibrosis therapeutics, the region is divided into the United States and Canada. In the US, many market leaders are developing efficient products owing to the rise in the need for cystic fibrosis drugs. For example, Virtex has developed three CFTR modulators drugs to fight diseases, namely Orkambi, Symdeko, and Kalydeco. Approved by the FDA, these CFTR drugs are used for the treatment of cystic fibrosis. Therefore, the development of new drugs to treat cystic fibrosis is predicted to propel the market growth in the future in this region. In the United States, the developing market is attributed to a substantial increase in cystic fibrosis in the region. In 2018, the US reigned the North American market and was expected to maintain the same throughout the forecast period. As per Cystic Fibrosis Foundation, cystic fibrosis affects about 30,000 people in the US, and new cases between 900 and 1000 are diagnosed every year.

Abbott Laboratories, headquartered in Abbott Park, Illinois, the US, is a pharmaceutical company that manufactures, develops, and markets a broad line of healthcare products. It has a business presence in 150 countries, including India, the US, Germany, Netherlands, China, Switzerland, Japan, and others. It has a partnership with the National Institutes of Health on brain research through Advancing Innovative Neurotechnologies initiative to improve the progress in neuroscience research.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
MARKET DYNAMICS
- MARKET DEFINITION
- KEY DRIVERS
  - ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
  - INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
  - RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
- KEY RESTRAINTS
  - STRINGENT REGULATION
  - LOW AWARENESS AMONG DEVELOPING ECONOMIES

KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
  - THREAT OF NEW ENTRY
  - THREAT OF SUBSTITUTION
  - BUYER’S POWER
  - SUPPLIER’S POWER
  - COMPETITIVE RIVALRY
- PESTEL ANALYSIS
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY INVESTMENT INSIGHTS
MARKET BY ROUTE OF ADMINISTRATION
- INHALE
- ORAL
MARKET BY DRUG CLASS
- CFTR MODULATORS
- BRONCHODILATORS
- MUCOLYTIC
- PANCREATIC ENZYME SUPPLEMENTS
GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - THE UNITED STATES
  - CANADA

COMPANY PROFILES
- ABBOTT LABORATORIES
- ABBVIE INC
- AGILENT TECHNOLOGIES INC
- ALLERGAN PLC
- HOFFMANN-LA ROCHE
- GILEAD SCIENCES INC
- GLAXOSMITHKLINE PLC
- JOHNSON & JOHNSON
- MYLAN N.V
- NOVARTIS AG
- PERKINELMER
- PFIZER INC
- PHARMAXIS LTD
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- VERTEX PHARMACEUTICALS INCORPORATED

TABLE LIST

TABLE 1: MARKET SNAPSHOT – VETERINARY VACCINE

TABLE 2: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 4: NORTH AMERICA INHALE MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: NORTH AMERICA INHALE MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 6: NORTH AMERICA ORAL MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: NORTH AMERICA ORAL MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 8: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 10: NORTH AMERICA CFTR MODULATORS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME

TABLE 12: NORTH AMERICA CFTR MODULATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 13: NORTH AMERICA BRONCHODILATORS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME

TABLE 15: NORTH AMERICA BRONCHODILATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 16: NORTH AMERICA MUCOLYTIC MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME

TABLE 18: NORTH AMERICA MUCOLYTIC MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 19: NORTH AMERICA PANCREATIC ENZYME SUPPLEMENTS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 20: NORTH AMERICA PANCREATIC ENZYME SUPPLEMENTS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 21: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 22: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

FIGURE LIST

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019

FIGURE 6: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)

FIGURE 7: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)

FIGURE 8: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019

FIGURE 9: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)

FIGURE 10: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)

FIGURE 11: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)

FIGURE 12: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)

FIGURE 13: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 14: THE UNITED STATES CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 15: CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

Segmentation

GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - THE UNITED STATES
  - CANADA

MARKET BY ROUTE OF ADMINISTRATION
- INHALE
- ORAL
MARKET BY DRUG CLASS
- CFTR MODULATORS
- BRONCHODILATORS
- MUCOLYTIC
- PANCREATIC ENZYME SUPPLEMENTS

Request Free Sample

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.